PHAP peptide

GeneTex

PHAP peptide

9

The peptide is used for blocking the activity of PHAP antibody (cat. no GTX25987). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37C.

Neutralisation/Blocking

Research Use Only

0.20 mg/ml

Unconjugated

ANP32A

acidic nuclear phosphoprotein 32 family member A

C15orf1, HPPCn, I1PP2A, LANP, MAPM, PHAP1, PHAPI, PP32, acidic leucine-rich nuclear phosphoprotein 32 family member A, acidic (leucine-rich) nuclear phosphoprotein 32 family, member A, acidic nuclear phosphoprotein pp32, cerebellar leucine rich acidic nuclear protein, epididymis secretory sperm binding protein, hepatopoietin Cn, inhibitor-1 of protein phosphatase-2A, leucine-rich acidic nuclear protein, mapmodulin, potent heat-stable protein phosphatase 2A inhibitor I1PP2A, putative HLA-DR-associated protein I, putative human HLA class II associated protein I

Apoptosis is related to many diseases and development. Caspase-9 plays a central role in cell death induced by a variety of apoptosis activators. Cytochrome c, after released from mitochondria, binds to Apaf-1, which forms an apoptosome that in turn binds to and activates procaspase-9. Activated caspase-9 cleaves and activates the effector caspases (caspase-3, -6 and -7), which are responsible for the proteolytic cleavage of many key proteins in apoptosis. The tumor suppressor putative HLA-DR-associated proteins (PHAPs) were recently identified as important regulators of mitochondrion apoptosis. PHAP appears to facilitate apoptosome-mediated caspase-9 activation and to stimulate the mitochondrial apoptotic pathway. PHAP was also shown to oppose both Ras- and Myc-medicated cell transformation.

-20°C

41116100

Human